Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A review of the literature

Medical Science Monitor

Volumn 13, Issue 4, 2007, Pages

  Veselka, Josef ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Alcohol ablation; Ethanol; Hypertrophic cardiomyopathy; Obstruction

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE;

CATHETER ABLATION; CLINICAL TRIAL; COMPLETE HEART BLOCK; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; HEART ARRHYTHMIA; HEART INFARCTION; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERMETHOD COMPARISON; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURGICAL TECHNIQUE;

CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ETHANOL; HEART SEPTUM; HUMANS;

EID: 34147109156     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Maron BJ, McKenna WJ, Danielson GK et al: American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic cardiomyopathy. Eur Heart J, 2003; 24: 1965-91
2. Maron MS, Olivotto I, Betocchi S et al: Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med, 2003; 348: 295-303
3. Thaman R, Gimeno JR, Murphy RT et al: Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart, 2005; 91: 920-25
4. Sigwart U: Non-surgical myocardial reduction of hypertrophic obstructive cardiomyopathy. Lancet, 1995; 346: 211-14
5. Gietzen FH, Leuner CJ, Obegassel L et al: Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provokable conditions. Circulation, 2002; 106: 454-49
6. Elliott PM, Gimeno JR, Tomé MT et al: Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J, 2006; 27: 1933-41
7. Aroney CN, Goh TH, Hourigan LA, Dyer W: Ventricular septal rupture following nonsurgical septal reduction for hypertrophic cardiomyopathy: treatment with percutaneous closure. Catheter Cardiovasc Interv, 2004; 61: 411-14
8. Chang SM, Nagueh SF, Spencer WH III, Lakkis NM: Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol, 2003; 42: 296-300
9. Lawrenz T, Obergassel L, Lieder F et al: Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pace, 2005; 28: 295-300
10. Seggewiss H, Faber L, Ziemssen P: Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiol Rev, 1999; 7: 316-23
11. Veselka J, Honěk T: Early remodeling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol, 2003; 88: 27-32
12. Veselka J, Procházková Š, Duchoňová R et al: Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv, 2004; 64: 231-35
13. Yoerger DM, Picard MH, Palacios IF et al: Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol, 2006; 97: 1511-14
14. Ruzyllo W, Chojnowska L, Demkow M et al.: Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J, 2000; 21: 770-77
15. Alam M, Dokainish H, Lakkis N: Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. A systematic review of literature. J Intervent Cardiol, 2006; 19: 319-27
16. Kimmelstiel CD, Maron BJ: Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation, 2004; 109: 452-55
17. Maron BJ, Dearani JA, Ommen SR et al: The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol, 2004; 44: 2044-53
18. Faber L, Seggewiss H, Welge D et al: Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Z Kardiol, 2003; 92: 39-47
19. Faber L, Meissner A, Ziemssen P et al: Percutaneous transluminal septal myocardial ablation for hypertrophic cardiomyopathy. Heart, 2000; 83: 326-31
20. Qin JX, Shiota T, Lever HM et al: Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol, 2004; 93: 171-75
21. Chang SM, Lakkis NM, Franklin J et al: Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation, 2004; 109: 824-27
22. Henein MY, O'Sullivan CA, Ramzy IS et al: Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 1999; 34: 117-22
23. Qin JX, Shiota T, Lever HM et al: Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal ablation and septal myectomy surgery. J Am Coll Cardiol, 2001; 38: 1994-2000
24. Runquist LH, Nielsen CD, Killip D et al: Electrocardiographic findings after alcohol septal ablation therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol, 2002; 90: 1020-22
25. Boltwood CM, Chien W: Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med, 2004; 351: 1914-15
26. Gietzen FH, Leuner CJ, Raute-Keinsen U et al: Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J, 1999; 20: 1342-54
27. Ziaee A, Lim M, Stewart R, Kern MJ: Coronary artery occlusion after transluminal alcohol septal ablation: differentiating dissection, spasm, and alcohol-induced no reflow. Catheter Cardiovasc Interv, 2005; 64: 204-8
28. Veselka J, Duchoňová R, Procházková Š et al: Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol, 2005; 95: 675-78
29. Nielsen CD, Killip D, Spencer WH III: Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: short-term results in 50 consecutive procedures. Clin Cardiol, 2003; 26: 275-79
30. Veselka J, Duchoňová R, Procházková Š et al: The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Kardiol Pol, 2004; 60: 133-35
31. Veselka J, Duchoňová R, Páleníč ková J et al: Age-related hemodynamic and morphologic differences in patients undergoing alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Circ J, 2006; 70: 880-84
32. Faber L, Welge D, Ziemssen P et al: Septal ablation for hypertrophic obstructive cardiomyopathy: an analysis of the patients with dissatisfactory reduction of the outflow gradient. J Am Coll Cardiol, 2002; 39(Suppl. B): 22B
33. Seggewiss H, Faber L, Gleichmann U, Horstkotte D: Age related acute results of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 2000; 35(Suppl.A): 188A
34. Gietzen FH, Leuner CJ, Obergassel L et al: Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart, 2004; 90: 638-44
35. Nagueh S, Lakkis NM, Middleton K et al: Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 1999; 34: 1123-28
36. Jassal DS, Neilan TG, Fifer MA et al: Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J, 2006; 27: 1805-10
37. Veselka J, Tesař D, Honěk T: Left ventricular remodeling and improvement of left ventricular relaxation after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Am J Cardiol, 2002; 90(Suppl.6A): 140H
38. Veselka J: Alcohol septal ablation for hypertrophic obstructive cardiomyopathy improves myocardial performance: a 24-month follow-up. Progr Coron Artery Dis, 2005; 6: 363-66
39. Veselka J, Procházková Š, Duchoňová R et al: Effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy on Doppler Tei index: a mid-term follow-up. Echocardiography, 2005; 22: 105-10
40. Mazur W, Nagueh SF, Lakkis NM et al: Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation, 2001; 103: 1492-96
41. Veselka J, Procházková Š, Duchoňová R et al: Echocardiographic examination before alcohol septal ablation can predict residual pressure gradient. Cor Vasa, 2004; 46: 524-27
42. Firoozi S, Elliott PM, Sharma S et al: Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic cardiomyopathy. Eur Heart J, 2002; 23: 1617-24
43. Nagueh SF, Ommen SR, Lakkis NM et al: Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol, 2001; 38: 1701-6
44. Ralph-Edwards A, Woo A, McCrindle BW et al: Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg, 2005; 129: 351-58
45. Singh M, Edwards WD, Holmes DR et al: Anatomy of the first septal perforating artery: A study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc, 2001; 76: 799-802
46. Faber L, Seggewiss H, Welge D et al: Echo-guided percutaneous septal ablation for symptomatic hypertrophic cardiomyopathy: 7 years of experience. Eur J Echocardiogr, 2004; 5: 347-55